A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy

Metachromatic Leukodystrophy (MLD) Clinical Trial

— EMBOLDEN  

Official title:

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03771898
• Other study ID #: SHP611-201
• Secondary ID: 2018-003291-12jR
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: April 30, 2019
• Est. completion date: March 6, 2025

Study information

• Verified date: June 2023
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of the study is to determine if SHP611 given by injection into the spinal fluid that surrounds the brain and spinal cord (intrathecal; IT) prolongs the time for children with Metachromatic Leukodystrophy (MLD) to retain the ability to move from place to place. Other aims of the study are to determine the effects of intrathecal administration of SHP611 on movement and speech functions and to learn how well SHP611 injected in the spinal fluid that surrounds the brain and spinal cord is tolerated. Study participants will receive SHP611 for about 2 years with the possibility of an extended treatment period.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 36
• Est. completion date: March 6, 2025
• Est. primary completion date: March 8, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 72 Months

Eligibility

Inclusion Criteria:

• The participant must have a documented diagnosis of MLD (Groups A-F):

1. Low ASA activity in leukocytes (compared to laboratory normal range).

2. Elevated sulfatides in urine.

• The participant must have a gait disorder due to spastic ataxia or weakness attributable to MLD by the investigator and documented by a primary care physician or a specialist physician by 30 months of age (Groups A-C, and F), or be minimally symptomatic and greater than or equal to (> =) 6 to less than (<) 18 months of age (Group D) or be early symptomatic and > =12 to < 18 months of age (Group E). Participants in Group E must have neurological symptoms either documented by either a primary care physician or a specialist physician.
• The participant's age at the time of informed consent, must be: Group A: 18 to 48 months of age; Group B: 18 to 72 months of age; Group C: 18 to 72 months of age; Group D: >= 6 to < 18 months of age; Group E: > = 12 to < 18 months of age; Group F: 18 to 72 months of age.
• The participant's GMFC-MLD category at screening must be: Group A: GMFC-MLD category of 1 or 2; Group B: GMFC-MLD category of 3; Group C: GMFC-MLD category of 4; Group D: minimally symptomatic, >= 6 to < 18 months of age, with the same arylsulfatase (ASA) allelic constitution as an older sibling with confirmed late infantile or juvenile onset MLD; Group E: early symptomatic, >= 12 to < 18 months of age with a GMFC-MLD category of 1 or 2 with a history of achieving stable walking (defined as at least 1 month of independent walking); Group F: GMFC-MLD category of 5 or 6.
• The participant and his/her parent/representative(s) must have the ability to comply with the clinical protocol.
• Participant's parent or legally authorized representative(s) must provide written informed consent prior to performing any study-related activities. Study-related activities are any procedures that would not have been performed during normal management of the participant.

Exclusion Criteria:

• Multiple sulfatase disorder as determined by abnormal activity of another lysosomal sulfatase (based upon the reference laboratory's normal range) or a known genetic disorder other than MLD.
• History of bone marrow transplant (BMT), hematopoietic stem cell transplantation (HSCT), or gene therapy; or undergoes BMT, HSCT, or gene therapy: at any point during the study.
• Primary presentation of MLD was behavioral or cognitive symptoms (per investigator's clinical judgment); behavioral symptoms that are secondary to motor deficits (example [eg], tantrums in response to loss of motor skills) are not exclusionary.
• The participant has any known or suspected hypersensitivity to agents used for anesthesia or has history of difficult airway or potential for airway compromise.
• Any other medical condition or serious comorbid illness that in the opinion of the investigator would preclude participation in the study.
• Participants with laboratory, ECG or vital sign abnormalities reflecting intercurrent illness that may compromise their safety during the trial should not be enrolled. Abnormal laboratory, vital sign and ECG results at screening should be reviewed with the Takeda medical monitor.
• The participant is enrolled in another clinical study that involves use of any investigational product (drug or device) within 30 days or 5 half-lives (whichever is longer) prior to study enrollment or at any time during the study.
• The participant has had prior exposure to SHP611.
• The participants must weigh > 11 pound (lbs) (5 kilograms [kg]).
• The participant has a condition that is contraindicated as described in the SOPH-A-PORT Mini S IDDD Instructions for Use (IFU)

1. The participant has had, or may have, an allergic reaction to the materials of construction.

2. The participant has shown an intolerance to an implanted device.

3. The participant's body size is too small to support the size of the SOPH-A-PORT Mini S Access Port.

4. The participant's drug therapy requires substances known to be incompatible with the materials of construction.

5. The participant has a known or suspected local or general infection.

6. The participant is at risk of abnormal bleeding due to a medical condition or therapy.

7. The participant has one or more spinal abnormalities that could complicate safe implantation or fixation.

8. The participant has a functioning Cerebro spinal fluid(CSF) shunt device. Filtering criteria for the selection of the matched external control group will be provided in the Statistical Analysis Plan (SAP)

Related Conditions & MeSH terms

• Leukodystrophy, Metachromatic
• Metachromatic Leukodystrophy (MLD)

Intervention

Drug:
• SHP611
Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.

Locations

Country	Name	City	State
Argentina	Hospital Universitario Austral - PIN	Ciudad Autónoma Buenos Aires	Buenos Aires
Belgium	UZ Antwerpen	Edegem
Brazil	Hospital de Clínicas de Porto Alegre	Porto Alegre
Canada	Stollery Children's Hospital University of Alberta	Edmonton	Alberta
Canada	Montreal Children's Hospital	Montreal	Quebec
Canada	Hospital for Sick Children	Toronto	Ontario
Canada	British Columbia Children's Hospital	Vancouver	British Columbia
France	Hôpital Bicêtre - Paris Sud	Le Kremlin-bicetre
France	CHU Lenval	Nice
Germany	Universitätsklinikum Hamburg Eppendorf	Hamburg
Germany	Universitätsklinikum Tübingen	Tubingen
Greece	Attikon University General Hospital	Chaidari	Attiki
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv
Italy	IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN	Roma
Japan	Kanazawa University Hospital	Kanazawa
Netherlands	VU Medisch Centrum	Amsterdam
Spain	Hospital Universitario Cruces	Barakaldo	Vizcaya
Spain	Hospital Vall d'Hebrón	Barcelona
United Kingdom	Birmingham Children's Hospital NHS Foundation Trust	Birmingham
United States	Rare Disease Research, LLC	Atlanta	Georgia
United States	Childrens Hospital Colorado	Aurora	Colorado
United States	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	University of Iowa Stead Family Children's Hospital	Iowa City	Iowa
United States	New York University Langone Medical Center	New York	New York
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Children's Hospital of Pittsburgh	Pittsburgh	Pennsylvania
United States	Mayo Clinic - PPDS	Rochester	Minnesota
United States	University of Utah	Salt Lake City	Utah
United States	Los Angeles Biomedical Research Institute at Harbor-UCLA	Torrance	California

Sponsors (2)

Lead Sponsor	Collaborator
Shire	Takeda Development Center Americas, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Belgium,  Brazil,  Canada,  France,  Germany,  Greece,  Israel,  Italy,  Japan,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response in Group A: Time to Loss of Locomotion Measured by Progression to Gross Motor Function Classification in Metachromatic Leukodystrophy (GMFC-MLD) at Week 106	The time to loss of locomotion, measured by progression to GMFC-MLD category 5 or higher, or death, whichever occurs first, up to Week 106, evaluated on participants in Group A. The GMFC-MLD is an instrument developed specifically for MLD participants. It is applicable from the age of 18 months onward and can be assessed retrospectively based on medical records as well as prospectively with directed examinations. The GMFC-MLD covers clinically relevant gross motor stages occurring in participants with metachromatic leukodystrophy (MLD) and consists of 7 categories of walking, sitting, locomotion, trunk and head control. The scoring range is from 0 (walking without support with quality of performance normal for age) to 6 (loss of any locomotion as well as loss of any head and trunk control).	Week 106
Secondary	Response in Group A: Maintenance of Gross Motor Function at Week 106 in Participants who do not Experience any Event within Week 106	The response in Group A gross motor function is defined as maintenance of gross motor function at Week 106, evaluated as participants who do not experience any event within Week 106, where event is defined as a decline in GMFC-MLD to category 5 or higher, or death. The GMFC-MLD is an instrument developed specifically for MLD participants. It is applicable from the age of 18 months onward and can be assessed retrospectively based on medical records as well as prospectively with directed examinations. The GMFC-MLD covers clinically relevant gross motor stages occurring in participants with metachromatic leukodystrophy (MLD) and consists of 7 categories of walking, sitting, locomotion, trunk and head control. The scoring range is from 0 (walking without support with quality of performance normal for age) to 6 (loss of any locomotion as well as loss of any head and trunk control).	Week 106
Secondary	Change From Baseline in Gross Motor Function Evaluated by Using the Gross Motor Function Classification in Metachromatic Leukodystrophy (GMFC-MLD) at Week 106 and End of Study (EOS)	The GMFC-MLD is an instrument developed specifically for MLD participants as described in above outcome measure. Change from baseline in gross motor function evaluated by using the GMFC-MLD will be reported.	Baseline, Week 106 and EOS (Week 211)
Secondary	Number of Participants With Unreversed Decline From Baseline in Metachromatic Leukodystrophy (GMFC-LMD) of More than 2 Categories	The GMFC-MLD is an instrument developed specifically for MLD participants as described in above outcome measure. Number of participants with unreversed Decline from baseline in metachromatic leukodystrophy (GMFC-LMD) of more than 2 categories evaluated on participants in Group A will be reported.	Baseline, Week 106 and EOS (Week 211)
Secondary	Time to Unreversed Decline From Baseline in Gross Motor Function Classification in GMFC-MLD of More Than 2 Categories	The GMFC-MLD is an instrument developed specifically for MLD participants as described in above outcome measure. Time to unreversed decline from baseline in GMFC-MLD of more than 2 categories is defined as any decline of more than 2-categories that has not reverted to a 2-category decline (or better) as of the last recorded observation.	Baseline up to EOS (Week 211)
Secondary	Change From Baseline in Cerebrospinal Fluid (CSF) Sulfatides Levels at Week 106 and End of Study (EOS)	Change from baseline in CSF sulfatides levels will be assessed.	Baseline, Week 106 and EOS (Week 211)
Secondary	Response in Group A: Maintenance of Gross Motor function in Participants at Week 106 Using Gross Motor Function Measure 88 (GMFM-88) Total Score Greater than or Equal to (>=) 40	The response in Group A gross motor function is defined as maintenance of gross motor function at Week 106, defined as a GMFM-88 total score >= 40. The GMFM-88 is a clinician-evaluated assessment of motor function across 5 dimensions: 1) lying and rolling 2) sitting 3) kneeling and crawling 4) standing and 5) walking, running, and jumping. Scoring is based on the percentage of accomplished tasks within each of the dimensions, and a total score is calculated by averaging each of the dimension scores. Each of the 88 items is rated on a 4-point scale: 0=does not initiate; 1=initiates; 2=partially completes; and 3=completes. GMFM-88 total score range is between 100 percent and 0 percent, with 0 percent corresponding to no mobility.	Week 106
Secondary	Time to Unreversed Decline From Baseline in Gross Motor Function Measure (GMFM)-88 Total Score of Greater Than (>) 20 Points or Unreversed Decline to Less Than (<) 40 Points Whichever Occurs First	The GMFM-88 is a clinician-evaluated assessment of motor function as described in above outcome measure. Time to unreversed decline from baseline at Week 106 and EOS in GMFM-88 total score of decrease of >20 points or unreversed decline to a score <40 points, whichever occurs first will be reported.	Baseline up to EOS (Week 211)
Secondary	Change From Baseline in Gross Motor Function Evaluated by Using Gross Motor Function Measure (GMFM)-88 Total Score at Week 106 and End of Study (EOS)	The GMFM-88 is a clinician-evaluated assessment of motor function as described in above outcome measure. Change from baseline in gross motor function evaluated by using the GMFM-88 total score will be reported.	Baseline, Week 106 and EOS (Week 211)
Secondary	Number of Participants With Gross Motor Function Measure (GMFM)-88 Total Score Decrease of <= 20 Points From Baseline and a Total Score > 40 at Week 106 and End of Study (EOS)	The GMFM-88 is a clinician-evaluated assessment of motor function as described in above outcome measure. Number of participants with GMFM-88 total score decrease of <= 20 points from baseline and a total score that is >= 40 will be reported.	Week 106, EOS (Week 211)
Secondary	Change From Baseline in Expressive Language Evaluated by Using the Expressive Language Function Classification in Metachromatic Leukodystrophy (ELFC-MLD) at Week 106 and End of Study (EOS)	The ELFC-MLD is a 5-category rating system to describe the regression of language abilities of participant with late infantile and juvenile MLD. The scoring range is from E0 (Communicates in complete sentences at a quality and performance normal for age) to E4 (Complete loss of expressive language). Change from baseline in expressive language evaluated by using the ELFC-MLD will be reported.	Baseline, Week 106 and EOS (Week 211)
Secondary	Ctrough of SHP611 in CSF	Ctrough is pre-dose trough concentration, defined as the drug concentration observed at the last planned timepoint prior to dosing, Ctrough of SHP611 CSF parameters at Weeks 0, 5, 9, 13, 26, 40, 53, 79, and 106 will be reported.	Predose at Weeks 0, 5, 9, 13, 26, 40, 53, 79, and 106
Secondary	Concentrations of SHP611 in CSF Following Single and Repeat IT Dosing of SHP611	The concentrations of SHP611 in CSF following single and repeat IT dosing of SHP611 will be evaluated.	Post dose at Week 0 and 106
Secondary	Maximum Observed Plasma Concentration (Cmax) of SHP611 in Serum	The Cmax of SHP611 in serum will be assessed.	Pre dose, 0.5, 1, 2, 4, 8, 12, 24 and 48 hours post dose on Week 0 and Week 106
Secondary	Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) of SHP611 in Serum	The AUC0-inf of SHP611 in serum will be assessed.	Pre dose, 0.5, 1, 2, 4, 8, 12, 24 and 48 hours post dose on Week 0 and Week 106
Secondary	Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-t) of SHP611 in Serum	The AUC0-t of SHP611 in serum will be assessed.	Pre dose, 0.5, 1, 2, 4, 8, 12, 24 and 48 hours post dose on Week 0 and Week 106
Secondary	Total Body Clearance (CL/F) of SHP611 in Serum	The CL/F of SHP611 in serum will be assessed.	Pre dose, 0.5, 1, 2, 4, 8, 12, 24 and 48 hours post dose on Week 0 and Week 106
Secondary	Ctrough of SHP611 in Serum at Weeks 0, 13, 26, 40, 53, 79, and 106	Ctrough is pre-dose trough concentration, defined as the drug concentration observed at the last planned timepoint prior to dosing, Ctrough of SHP611 in Serum at Weeks 0, 13, 26, 40, 53, 79, and 106 will be reported.	Predose at Weeks 0, 13, 26, 40, 53, 79, and 106
Secondary	Number of Participants With Treatment-emergent Adverse Event (TEAEs)	A treatment-emergent adverse event (TEAE) is defined as any event emerging or manifesting at or after the initiation of treatment with an investigational product or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the investigational product or medicinal product. Number of participants with TEAEs will be reported.	From start of study drug administration up to follow-up (Week 213)
Secondary	Change from Baseline in Clinical Laboratory Result at Week 106 and End of Study (EOS)	Clinical laboratory analysis includes serum chemistry, hematology, and urinalysis.	Baseline, Week 106 and EOS (Week 211)
Secondary	Change from Baseline in Physical Examination at Week 106 and End of Study (EOS)	Physical examination includes documentation of signs and symptoms of Metachromatic Leukodystrophy (MLD) (tone, reflexes, and vision).	Baseline, Week 106 and EOS (Week 211)
Secondary	Change from Baseline in Electrocardiogram (ECG) at Week 106 and End of Study (EOS)	2-lead ECG will be recorded and measured.	Baseline, Week 106 and EOS (Week 211)
Secondary	Change from Baseline in Cerebrospinal Fluid (CSF) Laboratory Parameters at Week 106 and End of Study (EOS)	CSF laboratory parameters includes chemistries and cell counts.	Baseline, Week 106 and EOS (Week 211)
Secondary	Number of Participants With Anti-SHP611 Antibodies	Number of participants with presence of Anti-SHP611 antibodies in CSF and serum will be reported.	Baseline, Week 106 and EOS (Week 211)
Secondary	Number of Participants With Adverse Events Related to SOPH-A-PORT Mini S Device	SOPH-A-PORT Mini S assessments will be evaluated using assessments of device implantation, device function, device longevity, and adverse events (AEs) associated with the implant surgery or device.	Up to EOS (Week 211)

External Links

•   To obtain more information on the study, click here/on this link